Logo image
Sign in
Variable response to antiplatelet therapy: What does it mean to clinicians?
Journal article   Peer reviewed

Variable response to antiplatelet therapy: What does it mean to clinicians?

Nezar Falluji and Steven R. Steinhubl
Cleveland Clinic Journal of Medicine, Vol.74(1)
2007

Abstract

acetylsalicylic acid adenosine diphosphate anticoagulant agent antithrombin antithrombocytic agent CD40 ligand citric acid clopidogrel cytochrome P450 inhibitor nonsteroid antiinflammatory agent PADGEM protein thromboxane B2 ticlopidine acute coronary syndrome atherosclerosis clinical trial drug dose comparison drug half life drug megadose drug potentiation drug response embolism environmental factor ex vivo study heart death heart infarction heredity human percutaneous transluminal angioplasty peripheral vascular disease physician prognosis protein expression protein urine level Review single drug dose single nucleotide polymorphism stroke thrombocyte aggregation inhibition thrombocyte function vascular disease
Ex vivo tests of platelet function show that platelet function and the response to antiplatelet therapy vary markedly from person to person. But just how clinically significant are ex vivo measurements of platelet function, and will changes we make based on such information translate into improved outcomes for patients? The authors summarize what is known and not known about the impact and clinical significance of variable response to antiplatelet therapy.

Metrics

1 Record Views

Details

Logo image